--- title: "Evidence: TSH and thyroid function" description: "Subclinical thyroid dysfunction is linked to increased cardiovascular risks, with treatment and screening guidelines varying but generally recommending…" url: "https://magellanlongevity.com/study/s148.md" canonical: "https://magellanlongevity.com/study/s148.html" html: "https://magellanlongevity.com/study/s148.html" type: "study" study_key: "s148" journal: "Eur Heart J" year: 2018 pmid: "28329380" doi: "10.1093/eurheartj/ehx050" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Evidence: TSH and thyroid function [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: TSH and thyroid function **HTML version:** https://magellanlongevity.com/study/s148.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s148 ## Citation | Field | Value | | --- | --- | | Journal | Eur Heart J | | Year | 2018 | | PMID | [28329380](https://pubmed.ncbi.nlm.nih.gov/28329380/) | | DOI | [10.1093/eurheartj/ehx050](https://doi.org/10.1093/eurheartj/ehx050) | | Study key | s148 | ## Takeaway Subclinical thyroid dysfunction is linked to increased cardiovascular risks, with treatment and screening guidelines varying but generally recommending intervention for significant TSH deviations and screening for at-risk populations. ## The question What is the current evidence regarding the association between subclinical thyroid dysfunction and cardiovascular disease, and what are the recommendations for screening and treatment? ## Hypothesis The review aims to update current evidence on the association between thyroid dysfunction and cardiovascular disease, as well as on screening and treatment of subclinical thyroid dysfunction. ## Methods This review summarizes evidence from individual participant data (IPD) analyses of prospective cohort studies from the international Thyroid Studies Collaboration and other small studies. ## Results Subclinical hypothyroidism (SHypo) is associated with increased coronary heart disease (CHD) mortality (HR 1.58 for TSH ">=" 10 mIU/L), increased risk of stroke, and heart failure (HF). SHypo also affects carotid intima media thickness (CIMT), diastolic function, peripheral vascular resistance, endothelial function, and lipid profile. Subclinical hyperthyroidism (SHyper) is associated with increased risk of atrial fibrillation (AF) (HR 1.68) and CHD events (HR 1.21). ## Conclusion Subclinical thyroid dysfunction is associated with various cardiovascular risks. Treatment for SHypo is suggested at TSH ">=" 10 mIU/L, and for SHyper at TSH "<" 0.1 mIU/L. Screening is advocated for individuals at risk for hypothyroidism, those over 60, and those with known CHD and HF. ## Limitations The TSH threshold for initiating treatment is unclear due to the absence of large randomized controlled trials. Recommendations on screening are discordant. ## Verbatim from the abstract > subclinical hypothyroidism is associated with increased coronary heart disease mortality ## Cardiovascular Risks Associated with Subclinical Thyroid Dysfunction | Measure | Hazard Ratio (HR) | | --- | --- | | SHypo (TSH ">= 10 mIU/L) CHD Mortality HR | 1.58 | | SHyper AF Risk HR | 1.68 | | SHyper CHD Events HR | 1.21 | *Hazard ratios for cardiovascular outcomes associated with subclinical thyroid dysfunction.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Thyroid (TSH) Home Panel | — | — | ## Reference 1. **Evidence: TSH and thyroid function** Eur Heart J 2018 · [PMID 28329380](https://pubmed.ncbi.nlm.nih.gov/28329380/) · [DOI 10.1093/eurheartj/ehx050](https://doi.org/10.1093/eurheartj/ehx050) > subclinical hypothyroidism is associated with increased coronary heart disease mortality ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s148.html#page","url":"https://magellanlongevity.com/study/s148.html","name":"Evidence: TSH and thyroid function","description":"Subclinical thyroid dysfunction is linked to increased cardiovascular risks, with treatment and screening guidelines varying but generally recommending…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s148.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: TSH and thyroid function","item":"https://magellanlongevity.com/study/s148.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s148.html#study","name":"Evidence: TSH and thyroid function","headline":"Evidence: TSH and thyroid function","datePublished":"2018","isPartOf":{"@type":"Periodical","name":"Eur Heart J"},"identifier":"PMID:28329380","url":"https://pubmed.ncbi.nlm.nih.gov/28329380/","sameAs":"https://doi.org/10.1093/eurheartj/ehx050","abstract":"Subclinical thyroid dysfunction is linked to increased cardiovascular risks, with treatment and screening guidelines varying but generally recommending intervention for significant TSH deviations and screening for at-risk populations."}]} ``` ## Related on Magellan Longevity - [Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart…](https://magellanlongevity.com/study/d24915118.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).